Novel diabetes drugs and the cardiovascular specialist

Sattar, N. , Petrie, M. C. , Zinman, B. and Januzzi Jr., J. L. (2017) Novel diabetes drugs and the cardiovascular specialist. Journal of the American College of Cardiology, 69(21), pp. 2646-2656. (doi: 10.1016/j.jacc.2017.04.014) (PMID:28545639)

141098.pdf - Accepted Version



Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce events in patients with diabetes and cardiovascular (CV) disease, a group common in cardiology clinics. The sodium-glucose cotransporter 2 inhibitor, empagliflozin, markedly and rapidly reduced CV death and heart failure hospitalization, likely with hemodynamic/metabolic-driven mechanisms of action. More recently, the glucagon-like peptide–1 receptor agonists liraglutide and semaglutide also reduced CV death and/or major adverse CV events, but did so more slowly and did not influence heart failure risks, suggesting alternative mechanisms of benefit. We will discuss drug therapy for diabetes relative to CV risk, briefly summarize key findings of CV benefit from recent trials, discuss potential mechanisms for benefits of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide–1 agonists, and suggest how such drugs might be embraced by CV specialists to reduce CV events and mortality in their patients.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Petrie, Professor Mark and Sattar, Professor Naveed
Authors: Sattar, N., Petrie, M. C., Zinman, B., and Januzzi Jr., J. L.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Journal of the American College of Cardiology
ISSN (Online):1558-3597
Published Online:22 May 2017
Copyright Holders:Copyright © 2017 The American College of Cardiology Foundation
First Published:First published in Journal of the American College of Cardiology 69(21):2646-2656
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher.

University Staff: Request a correction | Enlighten Editors: Update this record